06May
06May
LaunchPad Medical Wins a $2.5 Million NIH Grant to Improve Cranial Procedures
LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures. Read more >>
06May
Regroup Returns to Compete in 4th Annual ‘ASTORS’ Awards Program
Regroup Mass Notification, the Platinum Award Winner for Best Mass Notification Solution in the 2019 ‘ASTORS’ Homeland Security Awards Program, is pleased to announce the company has been nominated in the 2020 ‘ASTORS’ Awards Program. Read more >>
30Apr
Pittsburgh biotech firm involved in development of potential COVID-19 treatment
CytoAgents, a Pittsburgh biotech firm, and Quotient Sciences, are accelerating development of a COVID-19 treatment. Read more >>
30Apr
Local Gov’ts Get 90 Day Access to Regroup Mass Notification & CivicPlus
In response to the unprecedented COVID-19 pandemic, Regroup Mass Notification, a Nominated Competitor in the 2020 ‘ASTORS’ Homeland Security Awards Program, with its partner CivicPlus are offering cities and counties across the nation risk-free access to Regroup’s award-winning mass communication platform. Read more >>
30Apr
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced the publication of results from the double-blind, randomized, placebo-controlled Phase 2 trial assessing the safety and efficacy of lenabasum in 42 patients with diffuse cutaneous systemic sclerosis in Arthritis & Rheumatology. Read more >>
30Apr
Pittsburgh biotech firm involved in development of potential COVID-19 treatment
CytoAgents, a Pittsburgh biotech firm, and Quotient Sciences, are accelerating development of a COVID-19 treatment. The treatment would focus on what is called a “cytokine storm,” which is an excessive immune response that attacks the body. Read more >>
29Apr
District Ventures Capital Invests in Premama Wellness
District Ventures Capital ("District Ventures") announced today it has closed an equity investment with Premama Wellness ("Premama"), producers of a popular four-stage preconception through postnatal care supplement system based in Providence, Rhode Island. Read more >>
29Apr
How some companies survive, even thrive, in viral crisis
When the coronavirus struck the United States hard last month, 22-year-old entrepreneur David Zamarin knew his company needed a Plan B — fast. As the economy essentially shut down, demand for his stain-resistant coatings was sure to drop. Read more >>
26Apr